fbpx

Day

November 12, 2019
SNF472 significantly reduced progression of cardiovascular calcification in patients with end stage kidney disease (ESKD) receiving hemodialysis SNF472 treated patients had coronary artery calcium (CAC) volume score progression of 11% from baseline versus 20% in patients receiving placebo (P=0.016) SNF472 was well tolerated Results are remarkable as they have been achieved in patients who continued to...
Monday 18 November at 11:00 ET /16:00 GMT / 17:00 CET Sanifit will host a webcast on Monday November 18 at 11am ET / 5pm CET / 4pm GMT on the results of the international Phase 2b CaLIPSO study of lead candidate SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis. Joan Perelló, CEO and Alexander M....

News

Ancient DNA throws a ‘scientific hand grenade’ into the discussion about the arrival of humans in North America
23. July 2020
Danish researchers map key disease mechanism – and describe a completely new protein
20. July 2020
Five young medical students to conduct research in the US
9. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge